MarketBeat
10 Jul 2026, 07:03 UTC · 3h ago
Compass Pathways Eyes 2027 Launch as Psilocybin Depression Data Holds Up
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
MarketBeat
10 Jul 2026, 07:03 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Compass Pathways is proceeding with a rolling submission to the FDA for COMP360, with a target U.S. launch in the first half of 2027. — Moving toward regulatory submission is the primary value-unlocking milestone for a biotech company's lead asset.
+0.60Phase 3 COMP006 trial data showed 40% of a difficult-to-treat population achieved a clinically meaningful response by week six, with 'convincing separation' from control groups. — Positive efficacy data in a treatment-resistant population supports the likelihood of FDA approval and market viability.
+0.50The company identifies a potential U.S. market of 4 million patients and claims a competitive advantage over Spravato due to a significantly lower dosing frequency. — Reduced patient burden and a large addressable market increase the potential peak sales and commercial attractiveness.
+0.40Continue reading
6 related stories
Top 1 mover · tap to explore
COMP360 was described as generally well-tolerated through 26 weeks, with no imbalance in suicidal ideation across treatment arms. — A clean safety profile is critical for psychedelic therapies to avoid 'black box' warnings or regulatory rejection.
+0.30Which stocks this story touches
Positive Phase 3 trial data for COMP360 shows durability and safety, supporting a potential 2027 U.S. launch.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
2h ago
